Advancing The Role Of The Sglt2 Inhibitors In The T2d Treatment Paradigm | Latest News RSS feed

Advancing The Role Of The Sglt2 Inhibitors In The T2d Treatment Paradigm - Latest News


SGLT2 inhibitors: an emerging option for cardiologists?

But Boehringer’s trial goes beyond improved CV outcomes for diabetes patients to consider its product’s role for ... the use of SGLT2 inhibitors for the treatment of heart failure patients without ... read more

SGLT2 Inhibitors Work by Inducing Fasting State, Joslin Center Scientist Says

The study illuminates how the weight loss, reduction in fatty liver disease, and a decreased risk for cardiovascular disease happens in patients taking SGLT2 inhibitors ... patients with type 2 ... read more

Highlights: 2019 Cardiometabolic Health Congress West

The 3rd Annual CMHC West: Advancing ... The link between HF and T2D has also been emphasized in the latest cardiovascular outcome trials (CVOTs) of newer diabetes drugs. Specifically, sodium-glucose ... read more

Looking for another news?


ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes

ZynquistaTM now approved in the European Union for treatment of ... is an oral dual inhibitor of two proteins responsible for glucose regulation known as sodium-dependent glucose co-transporter types ... read more


SGLT2 inhibition — a novel strategy for diabetes treatment

The kidney plays a crucial role ... paradigm shift. As SGLT2 inhibitors do not target the major pathophysiological defects in T2DM — namely insulin resistance and impaired insulin secretion — they ... read more

Clear Consensus—Treat Cardiovascular Disease Concurrent with Diabetes

Among the key highlights from this diabetes treatment guidance are suggestions as to when to use and which to incorporate these newer therapies: SGLT2 inhibitors ... play a signficant role in the ... read more

Time for a "New Goalpost" in Cardiovascular Outcomes Trials, Kosiborod Suggests

While he acknowledged the criticisms about the restrictions and high costs of CVOTs, Kosiborod said that the FDA requirement has done much to advance the care for people with type 2 diabetes (T2D ... ... read more

New study reveals association between diuretic drug use in type 2 diabetes and risk of lower limb amputation

Recently, it has been observed that individuals with T2D who take canagliflozin, a member of a relatively new type of diabetes drug called an SGLT2 inhibitor ... "Further studies are needed to explore ... read more

How The Global Pharma Industry Will Shape Up In The Next 5 Years?

The 39 novel drugs approved in FY 2012 includes groundbreaking treatment for a form of cystic fibrosis, the first human cord blood product ever approved, and the first drugs to treat advanced basal .. ... read more

Renal, metabolic and cardiovascular considerations of SGLT2 inhibition

His research interests focus on the aetiology and treatment of prediabetes and type 2 diabetes. His research has helped to identify the mechanism of action of the SGLT2 inhibitor class of drugs on the ... read more

Poxel Announces Fourth Quarter and Full Year 2018 Financial Update

Imeglimin acts on all three key organs which play an important role in the treatment of type 2 diabetes ... therapy with existing hypoglycemic agents, including a DPP4 inhibitor, SGLT2 inhibitor, ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us